Paz-Ares, L <br/><br/>
A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System.  [electronic resource] 

 -  Journal of clinical pharmacy and therapeutics  Aug 2010 
 - 429-38 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2710 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2710.2009.01135.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--administration & dosage<br/>Carcinoma, Renal Cell--drug therapy<br/>Cost-Benefit Analysis<br/>Cytokines--therapeutic use<br/>Disease Progression<br/>Disease-Free Survival<br/>Drug Costs<br/>Drug Resistance, Neoplasm<br/>Female<br/>Health Care Costs<br/>Humans<br/>Immunotherapy<br/>Indoles--administration & dosage<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Markov Chains<br/>Middle Aged<br/>Models, Economic<br/>Palliative Care--economics<br/>Protein Kinase Inhibitors--administration & dosage<br/>Pyrroles--administration & dosage<br/>Quality-Adjusted Life Years<br/>Spain<br/>Sunitinib